EUCTR2007-000823-16-IT进行中（未招募）不适用
A multicentre, multinational, placebo-controlled, double-blind, randomized study to evaluate efficacy and safety of a perennial, sublingual, specific immunotherapy in patients with rhinoconjunctivitis with/without controlled asthma caused by grass pollen (ALLEGRA6). - ALLEGRA6
ALLERGOPHARMA JOACHIM GANZER KG0 个研究点目标入组 498 人开始时间: 2008年6月3日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 498
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Provision of informed consent before initiation of any study related procedures Male and female outpatients Age18 - 65 years IgE-mediated seasonal allergic rhinoconjunctivitis with or without controlled asthma caused by grass pollen documented by Positive skin prick test wheal for grass pollen > 5mm in diameter and Positive histamine (0.1% histamine free base) wheal >3mm and a negative NaCl control reaction <3mm Positive EAST > 1.5kU/L to grass pollens and Proven clinical relevance of grass pollen allergy by positive conjunctival provocation testing with grass pollen allergens and Main discomfort in the months May, June, July of the year For female patients with childbearing potential: (i.e., females are not chemically or surgically sterilised or females who are not post-menopausal) must have a negative serum pregnancy test before the baseline phase. Female patients must have a negative serum pregnancy test at enrolment and be willing to use a reliable method of birth control (i.e., double barrier method, oral contraceptive, implant, dermal contraception, long-term inject able contraceptive, intrauterine device, or tubar ligation) during the study, as judged by the investigator. Be able to understand and comply with the requirements of the study, as judged by the investigator For patients with bronchial asthma at entry: confirmed diagnosis and asthma classification as controlled ?according? GINA guidelines (version 2006). At the Beginning of the treatment phase: Rhinoconjunctivitis symptoms documented in the patients diary during the baseline season Patients must have demonstrated a Symptom - Score of at least 4 every day during the week following the peak pollen count in the baseline season.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Previous or other current specific immunotherapy with grass pollen allergens in any formulation For allergens which interfere with the grass pollen season: (Plantain, Nettle, Birch, Olive tree, Parietaria officinalis, Alternaria alternata, Cat epithelia, Dermatophagoides farinae, Dermatophagoides pteronyssinus): Sensitisation in the Skin Prick Test: wheal diameter of respective interfering allergen ≥ wheal diameter of grass pollen allergen Previous course of hyposensitisation against grass pollen or other allergens that are not known Patients who have undergone an unsuccessful course of specific immunotherapy with any allergen Clinically relevant rhinoconjunctival or respiratory symptoms related to other reasons PEF or FEV1 < 80% of predicted normal (ECCS) Uncontrolled or partly controlled asthma according GINA guidelines (version 2006) Febrile infections or inflammation of the respiratory tract at the time of inclusion Severe acute or chronic diseases, severe inflammatory diseases (liver, kidneys, metabolic diseases) Autoimmune diseases, immune-defects including immune-suppression, immune-complex-induced immunopathies Severe psychiatric and psychological disorders Treatment with beta-blockers (locally and systemically) Recurrent seizures Pregnancy and lactation period Concurrent participation in any other clinical trial or participation in any other clinical trial during the previous 30 days Low compliance or inability to understand instructions/study documents Involvement in the planning and conduct of the study (applies to both) Allergopharma Joachim Ganzer KG staff or staff at the study site. Patients being in any relationship of dependence with the Sponsor and/or with the Investigator Previous enrolment or randomisation of treatment in the present study Completed or ongoing treatment with anti-IgE-Antibody Completed or ongoing long-term treatment with tranquilizer psychoactive drugs Allergy treatment according to severity of symptoms with other than the following medication during the grass pollen season: Levocabastine nasal spray/eye drops, Loratadine/Cetirizin tablets, Salbutamol and exacerbation treatment with a short course of oral corticosteroids. Contra-indication for adrenalin (for example, acute or chronic symptomatic coronary heart disease, severe hypertension)
研究者
相似试验
进行中（未招募）
不适用
A multicenter, multinational, placebo-controlled, double-blind, randomized study to evaluate efficacy and safety of a perennial, sublingual specific immunotherapy in patielnts with rhinoconjunctivitis with/without controlled asthma caused by grass pollen (Allegra-6) - ALLEGRA6EUCTR2007-000823-16-DEAllergopharma Joachim Ganzer KG226
已完成
3 期
A clinical trial to evaluate the efficacy and safety of LC15 - 0444 in patients with type II diabetes.CTRI/2010/091/000353G Life Sciences Ltd180
进行中（未招募）
1 期
A study to learn more about asundexian (also called BAY2433334) for prevention of ischemic stroke in male and female participants aged 18 years and older who already had such a stroke due to a blood clot that formed outside the heart and travelled to the brain, or temporary stroke-like symptomsEUCTR2022-001067-27-NLBayer AG9,300
进行中（未招募）
1 期
A study to learn more about asundexian (also called BAY2433334) for prevention of ischemic stroke in male and female participants aged 18 years and older who already had such a stroke due to a blood clot that formed outside the heart and travelled to the brain, or temporary stroke-like symptomsPrevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attackMedDRA version: 20.0Level: PTClassification code 10049165Term: Cerebrovascular accident prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 22.1Level: LLTClassification code 10055221Term: Ischemic strokeSystem Organ Class: 100000004852MedDRA version: 20.1Level: LLTClassification code 10072760Term: Transient ischemic attackSystem Organ Class: 100000004852EUCTR2022-001067-27-DKBayer AG9,300
进行中（未招募）
1 期
A study to learn more about asundexian (also called BAY2433334) for prevention of ischemic stroke in male and female participants aged 18 years and older who already had such a stroke due to a blood clot that formed outside the heart and travelled to the brain, or temporary stroke-like symptomsEUCTR2022-001067-27-LTBayer AG9,300